Item 7.01 Regulation FD Disclosure.

Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors and analysts at various meetings between December 1, 2023 and December 31, 2023. During these meetings, the Company intends to reaffirm its guidance of at least $26.31 in diluted earnings per common share ("EPS") or at least $28.25 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2023 ("FY 2023"). This guidance is consistent with the guidance issued in Humana's press release dated November 1, 2023. The date and time of presentations to investors are available via the Investor Relations calendar of events on the Company's website at www.humana.com.

The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:

Diluted earnings per common share FY 2023 Guidance
GAAP
at least$26.31
Amortization of identifiable intangibles 0.53
Put/call valuation adjustments associated with Company's non-consolidating minority interest investments 1.13
Transaction and integration costs (0.38)
Change in fair market value of publicly-traded equity securities (0.01)
Impact of exit of employer group commercial medical products business 0.13
Accrued charge related to certain anticipated litigation expenses 0.84
Value creation initiatives 0.42
Cumulative net tax impact of non-GAAP adjustments (0.72)
Adjusted (non-GAAP) - FY 2023 projected
at least$28.25


Attachments

Disclaimer

Humana Inc. published this content on 01 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2023 12:31:33 UTC.